Evox’s Oxford - based Evox Therapeutics is poised to carry out phase 1 clinical trials of some of its rare disease candidates , after raising £ 35 ##m ( $ 45.4 m ) in series B funding from investors including Redmile Group and Google . Evox says the financing has put it in a position to take its protein replacement exosome , designed to treat Niemann - Pick disease type 2 , to the market .
Oxford - based Evox Therapeutics is poised to carry out phase 1 clinical trials of some of its rare disease candidates , after raising £ 35 ##m ( $ 45.4 m ) in series B funding from investors including Redmile Group and Google . Evox says the financing has put it in a position to take its protein replacement exosome , designed to treat Niemann - Pick disease type 2 , to the market .